

# Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/A35AB5D4615EN.html>

Date: April 2021

Pages: 57

Price: US\$ 125.00 (Single User License)

ID: A35AB5D4615EN

## Abstracts

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The company's proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. Alkermes is headquartered in Dublin, Ireland.

### Alkermes Plc Key Recent Developments

Mar 25,2021: Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy

Feb 11,2021: Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021

Feb 11,2021: Alkermes reports financial results for the fourth quarter and year ended

Dec. 31, 2020 and provides financial expectations for 2021

Feb 04,2021: Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results

Jan 06,2021: Alkermes announces updates to executive leadership team

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Alkermes Plc - Key Facts  
Alkermes Plc - Key Employees  
Alkermes Plc - Key Employee Biographies  
Alkermes Plc - Major Products and Services  
Alkermes Plc - History  
Alkermes Plc - Company Statement  
Alkermes Plc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Alkermes Plc - Business Description  
Product Category: Aristada/Aristada Initio  
Overview  
Performance  
Product Category: Vivitrol  
Overview  
Performance  
Geographical Segment: Ireland  
Performance  
Geographical Segment: Rest of World  
Performance  
Geographical Segment: The US  
Performance  
R&D Overview  
Alkermes Plc - Corporate Strategy  
Alkermes Plc - SWOT Analysis  
SWOT Analysis - Overview  
Alkermes Plc - Strengths  
Alkermes Plc - Weaknesses  
Alkermes Plc - Opportunities  
Alkermes Plc - Threats  
Alkermes Plc - Key Competitors

## **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Alkermes Plc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Mar 25, 2021: Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy

Feb 11, 2021: Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021

Feb 11, 2021: Alkermes reports financial results for the fourth quarter and year ended Dec. 31, 2020 and provides financial expectations for 2021

Feb 04, 2021: Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results

Jan 06, 2021: Alkermes announces updates to executive leadership team

Dec 11, 2020: Alkermes, Syneos Health, Neuro-Behavioral Clinical Research, Depression Bipolar and Support Alliance, and Matthew Shapiro Win the STARR Coalition STARR of Excellence 2020 Awards

Dec 10, 2020: Alkermes announces strategic value enhancement plan and continued board refreshment

Oct 29, 2020: Alkermes reports third quarter 2020 financial results and raises 2020 financial expectations

Jul 29, 2020: Alkermes reports second quarter 2020 financial results and issues 2020 financial expectations

Jun 29, 2020: Alkermes announces launch of 3rd annual Alkermes pathways research awards program

## **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Alkermes Plc, Key Facts  
Alkermes Plc, Key Employees  
Alkermes Plc, Key Employee Biographies  
Alkermes Plc, Major Products and Services  
Alkermes Plc, History  
Alkermes Plc, Other Locations  
Alkermes Plc, Subsidiaries  
Alkermes Plc, Key Competitors  
Alkermes Plc, Ratios based on current share price  
Alkermes Plc, Annual Ratios  
Alkermes Plc, Annual Ratios (Cont...1)  
Alkermes Plc, Interim Ratios  
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Alkermes Plc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios



## List Of Figures

### LIST OF FIGURES

Alkermes Plc, Performance Chart (2016 - 2020)

Alkermes Plc, Ratio Charts

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

## I would like to order

Product name: Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/A35AB5D4615EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A35AB5D4615EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970